Argo Biopharma begins dosing for Phase I BW-50218 trial
Argo Biopharmaceutical (Argo Biopharma) has dosed the first subject in its Phase I clinical trial assessing BW-50218, a small-interfering ribonucleic…
All articles by Salong Debbarma
Salong Debbarma
-
-
Massive Bio partners with OpenAI to broaden clinical trial access
Massive Bio has entered a partnership with OpenAI to expand global access to clinical studies through AI-driven parameterisation of protocols…
-
Cellenkos receives FDA approval for CK0801 Phase II clinical trial
Cellenkos has received the US Food and Drug Administration (FDA) clearance to begin its Phase II clinical trial of CK0801…
-
Oruka reports positive data from Phase IIa trial for plaque psoriasis
Oruka Therapeutics has reported positive interim data from the ongoing EVERLAST-A Phase IIa trial evaluating ORKA-001 in patients with moderate-to-severe…
-
Ascletis completes subject enrolment in Phase II ASC3 trial
Ascletis Pharma has completed subject enrolment in its 13-week US Phase II study of ASC30, an oral small molecule GLP-1…
-
Kyowa Kirin and Kura initiate Phase II trial of ziftomenib for AML
Kyowa Kirin and Kura Oncology have started a Japanese Phase II registrational study of oral menin inhibitor ziftomenib in adult…
-
Epitopea receives MHRA and REC approvals for OVACT ovarian cancer trial
Epitopea has secured approval from the Medicines and Healthcare products Regulatory Agency (MHRA) and the Regional Ethics Committee (REC) in…
-
CatalYm doses first patient in Phase II/III VINCIT trial
CatalYm has commenced dosing the first subject in its Phase II/III VINCIT trial, assessing the safety and efficacy of its…
-
Calluna concludes patient enrolment in Phase II trial for IPF
Calluna Pharma has concluded patient enrolment ahead of schedule in its global Phase II AURORA clinical trial evaluating CAL101 for…
-
ModeX starts dosing in MDX2003 trial for B-cell lymphoma
OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for relapsed or refractory B-cell…